載入中
NASDAQHealthcareBiotechnology
最新資料
US$0.4866
+US$0.0068 · +1.42%
Neumora Therapeutics, Inc. is a specialized biopharmaceutical company progressing through clinical trials, dedicated to advancing therapies for a range of neurological, psychiatric, and neurodegenerative conditions. Its most advanced candidate, navacaprant (also known as NMRA-140), is a novel, once-daily oral kappa opioid receptor antagonist currently undergoing Phase 3 clinical trials for the management of major depressive disorder. Additionally, NMRA-511 is in Phase 1 studies, targeting agitation experienced by individuals with Alzheimer's-related dementia. Another compound, NMRA-266, is also in Phase 1 clinical development, aimed at addressing schizophrenia and other related neuropsychiatric conditions. Beyond its clinical programs, Neumora maintains a preclinical pipeline featuring several promising candidates: NMRA-NMDA for schizophrenia, NMRA-CK1d (a CK1d inhibitor initiative) for amyotrophic lateral sclerosis (ALS), NMRA-NLRP3 for specific neurodegenerative ailments, and NMRA-GCase for Parkinson's disease. Tracing its origins to a 2019 incorporation, the company, initially known as RBNC Therapeutics, Inc., adopted its current name, Neumora Therapeutics, Inc., in October 2021. Its corporate headquarters are situated in Watertown, Massachusetts.
一般交易時段
US$0.4866
+US$0.0068 · +1.42%
盤中時間採用ET。市場資料可能有所延遲。
Neumora Therapeutics, Inc. is a specialized biopharmaceutical company progressing through clinical trials, dedicated to advancing therapies for a range of neurological, psychiatric, and neurodegenerative conditions. Its most advanced candidate, navacaprant (also known as NMRA-140), is a novel, once-daily oral kappa opioid receptor antagonist currently undergoing Phase 3 clinical trials for the management of major depressive disorder. Additionally, NMRA-511 is in Phase 1 studies, targeting agitation experienced by individuals with Alzheimer's-related dementia. Another compound, NMRA-266, is also in Phase 1 clinical development, aimed at addressing schizophrenia and other related neuropsychiatric conditions. Beyond its clinical programs, Neumora maintains a preclinical pipeline featuring several promising candidates: NMRA-NMDA for schizophrenia, NMRA-CK1d (a CK1d inhibitor initiative) for amyotrophic lateral sclerosis (ALS), NMRA-NLRP3 for specific neurodegenerative ailments, and NMRA-GCase for Parkinson's disease. Tracing its origins to a 2019 incorporation, the company, initially known as RBNC Therapeutics, Inc., adopted its current name, Neumora Therapeutics, Inc., in October 2021. Its corporate headquarters are situated in Watertown, Massachusetts.
日內區間
目前US$0.4866
52週區間
目前US$0.4866
盤中時間採用ET。市場資料可能有所延遲。
Neumora Therapeutics, Inc. is a specialized biopharmaceutical company progressing through clinical trials, dedicated to advancing therapies for a range of neurological, psychiatric, and neurodegenerative conditions. Its most advanced candidate, navacaprant (also known as NMRA-140), is a novel, once-daily oral kappa opioid receptor antagonist currently undergoing Phase 3 clinical trials for the management of major depressive disorder. Additionally, NMRA-511 is in Phase 1 studies, targeting agitation experienced by individuals with Alzheimer's-related dementia. Another compound, NMRA-266, is also in Phase 1 clinical development, aimed at addressing schizophrenia and other related neuropsychiatric conditions. Beyond its clinical programs, Neumora maintains a preclinical pipeline featuring several promising candidates: NMRA-NMDA for schizophrenia, NMRA-CK1d (a CK1d inhibitor initiative) for amyotrophic lateral sclerosis (ALS), NMRA-NLRP3 for specific neurodegenerative ailments, and NMRA-GCase for Parkinson's disease. Tracing its origins to a 2019 incorporation, the company, initially known as RBNC Therapeutics, Inc., adopted its current name, Neumora Therapeutics, Inc., in October 2021. Its corporate headquarters are situated in Watertown, Massachusetts.
日內區間
目前US$0.4866
52週區間
目前US$0.4866
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 銷貨成本 | 500萬 USD | — | 66.8萬 USD | — | — |
| 毛利 | −500萬 USD | — | −66.8萬 USD | — | — |
| 研究與開發 | 1.76億 USD | 2.01億 USD | 1.43億 USD | 1.05億 USD | 2.13億 USD |
| 銷售、一般及管理費用 | 6009.1萬 USD | 6253.7萬 USD | 4480.7萬 USD | 3112.1萬 USD | 2454.7萬 USD |
| 營業費用 | 2.36億 USD | 2.63億 USD | 1.88億 USD | 1.36億 USD | 2.37億 USD |
| 利息收入 | 834.4萬 USD | 1993.3萬 USD | 1661.1萬 USD | 456.1萬 USD | — |
| 利息支出 | 321.9萬 USD | — | — | — | — |
| 折舊和攤銷 | 20.8萬 USD | 63.1萬 USD | 66.8萬 USD | 59.4萬 USD | 53.8萬 USD |
| 營業利益 | −2.41億 USD | −2.63億 USD | −1.88億 USD | −1.36億 USD | −2.37億 USD |
| 淨利 | −2.37億 USD | −2.44億 USD | −2.36億 USD | −1.31億 USD | −2.37億 USD |
公司資料更新於 2026年10月9日。
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$4.50
上漲空間 824.78%報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI456.93萬0.00%2.3兆 USD0.03%US$381.76+0.58%
Vanguard Extended Market ETFVXF149.77萬0.00%954億 USD0.05%US$234.89+0.75%
iShares Russell 2000 ETFIWM122.79萬0.00%776.97億 USD0.19%US$279.02+0.52%
Vanguard Russell 2000 ETFVTWO78.41萬0.00%180億 USD0.06%US$112.71+0.54%
iShares Russell 2000 Growth ETFIWO50.39萬0.00%140.44億 USD0.24%US$356.73+0.92%
iShares Biotechnology ETFIBB28.62萬0.00%104.14億 USD0.44%US$206.7+3.10%
Vanguard Health Care ETFVHT26.4萬0.00%220億 USD0.09%US$319.46+1.79%
Schwab U.S. Small-Cap ETFSCHA25.66萬0.00%217.28億 USD0.03%US$32.805+0.44%Vanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFiShares Russell 2000 ETFIWMVanguard Russell 2000 ETFVTWOiShares Russell 2000 Growth ETFIWOiShares Biotechnology ETFIBBVanguard Health Care ETFVHTSchwab U.S. Small-Cap ETFSCHAAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
